Tirzepatide, a dual GIP/GLP-1R agonist, has demonstrated efficacy in reducing body weight and limiting progression to type 2 diabetes in patients with obesity and prediabetes [397], suggesting that combined GIP/GLP-1 therapy may offer synergistic benefits in obesity-associated IBD. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.